Last reviewed · How we verify
Immuncell-LC
Immuncell-LC is an autologous cell therapy that activates and expands a patient's own immune cells to enhance anti-tumor immunity.
Immuncell-LC is an autologous cell therapy that activates and expands a patient's own immune cells to enhance anti-tumor immunity. Used for Advanced gastric cancer, Colorectal cancer.
At a glance
| Generic name | Immuncell-LC |
|---|---|
| Also known as | Activated T lymphocyte, Autologous activated T lymphocyte |
| Sponsor | GC Cell Corporation |
| Drug class | Autologous cell therapy |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Immuncell-LC involves ex vivo activation and expansion of lymphocytes derived from the patient's own blood, which are then reinfused to boost cellular immune responses against cancer. The therapy leverages the patient's endogenous immune system by culturing and amplifying cytotoxic T cells and natural killer cells to target malignant cells. This autologous approach aims to provide personalized immunotherapy with reduced rejection risk.
Approved indications
- Advanced gastric cancer
- Colorectal cancer
Common side effects
- Fever
- Chills
- Fatigue
- Infusion-related reactions
Key clinical trials
- Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea (PHASE3)
- Retrospective Study of Long-Term Survival of "Immuncell-LC" in Patients Undergoing Curative Resection for HCC in Korea
- Evaluate the Efficacy and Safety of Activated T-lymphocyte Cell Therapy in Advanced Pancreatic Cancer (PHASE2)
- Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients (PHASE3)
- Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced HCC (PHASE2)
- Long Term Follow-Up Study of Immuncell-LC Group and Non-Treatment Group in Hepatocellular Carcinoma Patients.
- Evaluate the Efficacy and Safety of 'Immuncell-LC' in Patients Undergoing Liver Transplantation (PHASE1, PHASE2)
- Safety and Efficacy of "Immuncell-LC" in TACE Therapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Immuncell-LC CI brief — competitive landscape report
- Immuncell-LC updates RSS · CI watch RSS
- GC Cell Corporation portfolio CI